Track NervGen Pharma Common stock's long-term debt ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), NGEN shows a long-term debt of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NGEN's long-term debt is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether NervGen Pharma Common stock is outperforming or lagging.
Tracking NGEN's long-term debt over time shows whether NervGen Pharma Common stock is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has NervGen Pharma Common stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.
NervGen Pharma Common stock's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.